Physician profile
Kumar P Yogesh
NPI 1366430993
$13,666.87
in general payments reported to CMS, 2019-2025
38 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,100 · 2020: $1,945 · 2021: $2,104 · 2022: $1,956 · 2023: $2,182 · 2024: $1,709 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,162 · Education: $200 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,161.61 |
| Education | $200.22 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,043.77 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,664.51 | 2019-2025 | Ofev, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,486.04 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Harmony Biosciences LLC | $775.29 | 2022-2025 | Wakix |
| Mylan Specialty L.P. | $696.82 | 2019-2024 | Yupelri |
| Novo Nordisk INC | $611.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $550.74 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $457.37 | 2019-2025 | Winrevair |
| Novartis Pharmaceuticals Corporation | $340.73 | 2022-2024 | |
| United Therapeutics Corporation | $320.16 | 2022-2025 | Tyvaso, Tyvaso |
| Lilly USA, LLC | $311.55 | 2019-2025 | Zepbound |
| Sunovion Pharmaceuticals INC. | $304.44 | 2019-2021 | |
| Insmed, INC. | $302.44 | 2020-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $292.99 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $270.37 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $219.21 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $211.14 | 2020-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $202.81 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Pfizer INC. | $186.05 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $143.96 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.42 | 2021-2022 | |
| Genentech USA, INC. | $133.92 | 2019-2020 | |
| Verona Pharma, INC. | $126.87 | 2025 | Ohtuvayre |
| Electromed, INC. | $123.63 | 2023-2025 | Smartvest |
| Baxter Healthcare | $93.28 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Eisai INC. | $90.69 | 2020-2022 | |
| Intuitive Surgical, INC. | $90.60 | 2024 | |
| Amgen INC. | $90.09 | 2020-2025 | |
| Shield Therapeutics INC | $81.15 | 2024 | |
| Abbvie INC. | $79.08 | 2021-2023 | Vraylar, Ubrelvy |
| Esperion Therapeutics, INC. | $42.27 | 2021-2024 | Nexletol |
| Pulmonx Corporation | $35.87 | 2022-2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Circassia INC. | $32.91 | 2019 | |
| Viatris Specialty LLC | $32.67 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.63 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $18.34 | 2022 | |
| Advanced Respiratory, INC | $16.17 | 2021 | |
| Allergan, INC. | $14.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Yogesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.